News

Videos

Anti-Emesis For Patients With Gastrointestinal Cancers

08/24/2023

At the 2023 World Congress on Gastrointesinal Cancers, Matti Aapro, MD, discusses how to best address emesis among patients with gastrointestinal cancers.

At the 2023 World Congress on...

08/24/2023

Oncology

Videos

Bemarituzumab Plus FOLFOX Superior to FOLFOX Alone Among Patients With FGFR2b-Positive Metastatic Gastric Cancer

08/22/2023

Zev Wainberg , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presented results from the final analysis of the phase 2 FIGHT trial.

At the 2023 World Congress on...

08/22/2023

Oncology

Patrick Tan, MD, PhD, Genome Institute of Singapore

Videos

New Strategies for Molecular Classification in Gastric Cancer

08/22/2023

Patrick Tan , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Patrick Tan, MD, PhD, presented a keynote lecture on new strategies to achieve molecular classification in gastric cancer that can potentially inform the future treatment landscape.

At the 2023 World Congress on...

08/22/2023

Oncology

Antonella Cammarota, MD, Humanitas University

Videos

Impact of Prior Chemotherapy Administration on Intratumor Heterogeneity of CLDN18.2-Positive Gastroesophageal Cancers

08/21/2023

Antonella Cammarota , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Antonella Cammarota, MD, presented results from a study relating prior chemotherapy administration with heterogeneity of CLDN18.2 among patients with resectable gastroesophageal cancers.

At the 2023 World Congress on...

08/21/2023

Oncology

Giovanni Randon, MD, Fondazione IRCCS Istituto Nazionale dei Tumori

Videos

Relationship Between Clinicopathological Features and Immunotherapy Benefit Among Patients With dMMR/MSI-High Metastatic or Unresectable Gastric Cancer

08/17/2023

Giovanni Randon , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Giovanni Randon, MD, presented results from a study relating clinicopathological features and immunotherapy benefit among patients with dMMR/MSI-high metastatic or unresectable gastric...

At the 2023 World Congress on...

08/17/2023

Oncology

Videos

Addition of Trastuzumab to Perioperative Chemotherapy Improved Response Rates Among Patients with HER2-Positive Gastric or Gastroesophageal Junction Cancer

08/11/2023

Anna Dorothea Wagner , PD;

At the 2023 World Congress on Gastrointestinal Cancers, Anna Wagner, MD, discusses the addition of trastuzumab to perioperative chemotherapy for patients with HER2-positive gastric or gastroesophageal junction cancer.

At the 2023 World Congress on...

08/11/2023

Oncology

News

Trastuzumab Plus Ramucirumab and Paclitaxel Shows Promise Among Patients With Second-Line HER2-Positive, Advanced Gastric or Gastroesophageal Junction Cancer

08/10/2023

Allison Casey ;

In a phase 1b/2 study, trastuzumab plus ramucirumab and paclitaxel showed promise in the second-line setting for patients with HER2-positive gastric or gastroesophageal junction cancer.

In a phase 1b/2 study,...

08/10/2023

Oncology

Videos

Targeting KRAS in Gastrointestinal Cancers

07/14/2023

At the 2023 World Congress on Gastrointestinal Cancers, John Strickler, MD, reviews the currently available and upcoming strategies in targeting KRAS in gastrointestinal cancers.

At the 2023 World Congress on...

07/14/2023

Oncology

Van Morris, MD, MD Anderson Cancer Center

Videos

Ipilimumab Added to Nivolumab Does Not Significantly Improve Survival Outcomes for Patients With Squamous Cell Carcinoma of the Anal Canal

07/13/2023

Van Morris , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Van Morris, MD, presented results from a phase 2 study evaluating the addition of ipilimumab to nivolumab for patients with previously treated, unresectable or metastatic squamous cell...

At the 2023 World Congress on...

07/13/2023

Oncology

Michael White, MD, MD Anderson Cancer Center

Videos

Mutational Signature Similarities and Differences Between Appendiceal Adenocarcinoma and Colorectal Cancer

07/13/2023

Michael White , MD;

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, there were distinct mutational differences noted between appendiceal adenocarcinoma and colorectal cancer.

According to a study presented...

07/13/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology